Indication
Chronic intestinal amebiasis
Chronic intestinal amebiasis is a persistent, non-fulminant parasitic infection of the large intestine caused by mucosal colonization and tissue invasion by the protozoan *Entamoeba histolytica*. Read more about Chronic intestinal amebiasis
5 drugs 5 manufacturers
Drugs that treat it
Common Chronic intestinal amebiasis therapies.
PAROMOMYCIN SULFATE
PAROMOMYCIN SULFATE
HUMATIN (paromomycin sulfate)
PAROMOMYCIN SULFATE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonChronic intestinal amebiasis is a persistent, non-fulminant parasitic infection of the large intestine caused by mucosal colonization and tissue invasion by the protozoan *Entamoeba histolytica*.
It predominantly affects individuals in resource-limited regions with inadequate sanitation, as well as travelers, immigrants, or institutionalized populations exposed via the fecal-oral route.
Pathophysiologically characterized by ongoing colonic mucosal ulceration and inflammation, this chronic state typically manifests with recurrent or low-grade diarrhea—often alternating with constipation—alongside abdominal cramping, flatulence, fatigue, and weight loss that can clinically mimic inflammatory bowel disease.
If left untreated, chronic mucosal invasion can progress to localized inflammatory mass lesions, termed amebomas, or lead to extraintestinal complications.
- medlineplus.gov
Chronic intestinal amebiasis is a persistent, non-fulminant parasitic infection of the large intestine caused by mucosal colonization and tissue invasion by the protozoan *Entamoeba histolytica*
- cdc.gov
Chronic intestinal amebiasis is a persistent, non-fulminant parasitic infection of the large intestine caused by mucosal colonization and tissue invasion by the protozoan *Entamoeba histolytica* It predominantly affects individuals in resource-limited regions with inadequate sanitation, as well as travelers, immigrants, or institutionalized populations exposed via the fecal-oral route If left untreated, chronic mucosal invasion can progress to localized inflammatory mass lesions, termed amebomas...
- cdc.gov
It predominantly affects individuals in resource-limited regions with inadequate sanitation, as well as travelers, immigrants, or institutionalized populations exposed via the fecal-oral route
- nih.gov
Pathophysiologically characterized by ongoing colonic mucosal ulceration and inflammation, this chronic state typically manifests with recurrent or low-grade diarrhea—often alternating with constipation—alongside abdominal cramping, flatulence, fatigue, and weight loss that can clinically mimic inflammatory bowel disease
- nih.gov
Pathophysiologically characterized by ongoing colonic mucosal ulceration and inflammation, this chronic state typically manifests with recurrent or low-grade diarrhea—often alternating with constipation—alongside abdominal cramping, flatulence, fatigue, and weight loss that can clinically mimic inflammatory bowel disease
- nih.gov
Pathophysiologically characterized by ongoing colonic mucosal ulceration and inflammation, this chronic state typically manifests with recurrent or low-grade diarrhea—often alternating with constipation—alongside abdominal cramping, flatulence, fatigue, and weight loss that can clinically mimic inflammatory bowel disease If left untreated, chronic mucosal invasion can progress to localized inflammatory mass lesions, termed amebomas, or lead to extraintestinal complications
Personalize your experience
Follow Chronic intestinal amebiasis and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.